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Abstract This study was designed to determine whether the benefit of adding salmeterolwas superior to doubling
the dose of fluticasonepropionate (FP) over 6months, comparedto a controlgroupwhoremainedon a lowerdose of FP.
The multi-centre, double-blind, parallel group study involved 496 symptomatic asthmatic patients with a history of ex-
acerbations on 500^800 micrograms (mg) inhaled corticosteroids (ICS) twice daily (b.d.) in a broadly representative
group of 100 hospitals and general practices in six countries. Two doses of FPF250 mg b.d. (FP250) or 500 mg b.d.
(FP500)Fwere compared with the lower dose of FP plus a long-acting b2-agonist, salmeterol 50 mg b.d. (SM/FP250).
Patients symptomatic on the run-in dose of FP250 alone formed the control group in the treatment period.Over 6
months, SM/FP250 significantly improvedmeanmorning peak expiratory flow rates (amPEF) by 42.1l/min, more than
twice the improvement achievedwith either dose of FP alone. SM/FP250 also resulted inmore symptom-free days and
nights (Po0.002) and days andnightswithno reliefmedication (Po0.001).Thenumberof severe exacerbationswaslow:
3, 6 and 8% in the SM/FP250, low- and high-dose FP groups, respectively.This study confirms that adding salmeterol to
low-dose inhaled FPoffers greater improvements than eithermaintaining or doubling the dose of FP. Significant benefit
was gained from adding salmeterol in a group of patients who appeared to have been at the top of their steroid dose^
response curvereceiving FP250.Therewasno evidenceoftolerance anda lowincidenceofexacerbationsin alltreatment
groups.r2003 Publishedby Elsevier Science Ltd.
doi:10.1053/rmed.2003.1483, available online at http://www.sciencedirect.com
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The addition of inhaled long-acting b-agonists, has been
shown to improve lung function and control symptoms
and exacerbations more e¡ectively than doubling the
dose of inhaled corticosteroids (ICS), in patients with
varying degrees of asthma severity, symptomatic on
ICS. Indeed, the addition of a long-acting b-agonist to a
patient’s current dose of ICS is now an established alter-
native to increasing the ICS dose, in International asthma
guidelines (1^3).
Greening et al. (4) were the ¢rst to report that adding
the long-acting b-agonist salmeterol to existing beclo-
metasone dipropionate (BDP) therapy was more e¡ec-
tive than doubling the ICS dose. These ¢ndings have
been con¢rmed in subsequent studies with other ICSReceived 5 June 2992, accepted in revised form 2 December 2002.
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Hospital,DucaneRoad,London,W120NN,UK.Fax: +44-20-8743-9733
E-mail address: p.ind@ic.ac.uk (P.W. Ind)and long-acting b-agonists (5^9), and a meta-analysis
of salmeterol studies (10). However, none of the studies
to date have included a control group continuing
the initial (run-in) dose of ICS. The presence of patients
symptomatic on a ‘‘constant dose’’ control arm is
important in order to assess the real e¡ect of treatment
(i.e. adding a long-acting b-agonist) rather than a trial
e¡ect.
Only one other published study has included a ‘‘con-
stant dose’’ control arm, but this study investigated the
e¡ects of adding theophylline to low dose ICS, in com-
parisonwith doubling the ICS dose (11).
Our study was undertaken to gain additional under-
standing of the SM/FP250 combination over a long dura-
tion in asthmatics uncontrolled on ICS alone. In
particular, the study was designed to see whether the
bene¢t of adding salmeterolwas superior to that of dou-
bling the dose of FP to 500mcg b.d., while also including
a control groupwho continued treatmentwith low-dose
FP (250mcg b.d.).
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Study design
This multi-centre, randomised, double-blind, double-
dummy, parallel group study was conducted in100 hospi-
tal and primary care centres in the United Kingdom,
Italy, Canada, Denmark, Iceland and the Republic of Ire-
land, between January 1995 and November 1996. The
study was conducted in accordance with local Good
Clinical Practice Guidelines and with the Declaration of
Helsinki (12).
Study population
Patients with asthma, aged between 16 and 75 years,
who were currently symptomatic on BDP 500^800mg
twice daily (or equivalent) delivered via a metered dose
inhaler (MDI) were eligible for inclusion in the study. Pa-
tients had to demonstrate correct usage of an MDI and
peak expiratory £ow (PEF) meter, and at the ¢rst clinic
visit, had to have a PEF of less than 85% of post-broncho-
dilator PEF determined15min after inhalation of salbuta-
mol (400mg) via a Volumatic spacer. Patients were
required to have at least two documented asthma ex-
acerbations leading to a change in therapy or hospitalisa-
tion in the previous year with at least one of these
episodes having occurred during the last 6 months.
Other asthmamedicationswerepermitted (with the ex-
ception of additional inhaled ICS and b2-agonists). Pa-
tients were excluded if they were receiving continuous
oral corticosteroids, if they had any serious uncontrolled
systemic disease or their participation was deemed un-
suitableby thephysician. In order to enter the treatment
phase of the study patients also had to demonstrate a
period variation in PEF of at least 15% (highest evening
value-lowest morning value as a percentage of highest
PEF) over the last10 days and/or nights of the run-in per-
iod and to have sub-optimal PEF, with average PEF over
the last10 days of the run-in not exceeding 90% of post-
bronchodilator PEF (measured at visit1).
Treatment
Study treatments were given by MDI. During a 4-week
initial run-in period patients were treated with FP 250
mcg b.d. and used salbutamol as required for sympto-
matic relief. In order to minimise any non-speci¢c re-
sponses during this period, patients were unaware of
their ICS dose. At the end of the run-in period, patients
were randomised to one of the following treatments for
24 weeks: (i) SM/FP250mg b.d. (SM50mg b.d. plus
FP250mg b.d.), (ii) FP500mg b.d. or (iii) FP250mg b.d. Pa-
tients and physicians were blinded to treatment inter-
vention. All patients took salbutamol as required for
symptom relief and were given an unblinded supply ofFP 250mgper pu¡ and oral prednisolone for use in an ex-
acerbation.
Measurements and assessments
Patients were assessed in the clinic at weeks1 (visit 1), 2
(visit1a) and 4 (visit 2) of the run-in period, and atweeks
6 (visit 3), 12 (visit 4), 18 (visit 5) and 24 (visit 6) of the
treatment period. Mini Wright peak £ow meters were
used by all patients throughout the study, with training
in the use of meters at each clinic visit.The best of three
PEF values, before patients took their studymedication,
was recorded in daily record cards each morning and
evening throughout the study. Night-time symptoms,
asthma symptoms on wakening, number and severity of
exacerbations and use of relief medication were also re-
corded in daily record cards.Diurnal variation in PEFwas
calculated daily for each patient as highest^lowest/high-
est. Percent predicted PEF values were calculated using
European standardised reference ranges (13).Night-time
symptoms were scored by the patient using a 5-point
scale (0^4) where 0 indicated no symptoms, and 4 indi-
cated symptoms so severe that thepatientwas unable to
sleep at all.Daytime symptomswere scored on a 6 point
scale (0^5)with a score of 0 indicatingno symptoms, and
a score of 5 indicating symptoms so severe that the pa-
tient could not go to work/school/college, or perform
normal daily activities.
Exacerbations were assessed by the physician and ca-
tegorised (4) as mild (requiring clinically signi¢cant in-
crease in relief medication); moderate (requiring the use
of additional corticosteroid) or severe (requiring emer-
gency hospital treatment). The number and severity of
asthma exacerbations and the time to resolution were
assessed at each scheduled visit.
Withdrawals from the study were recorded; withdra-
wals due to lack of e⁄cacy were distinguished from
other withdrawals. Both the physician and the patient
made an assessment of the e¡ectiveness of the treat-
ment of each patient’s asthma at the beginning and end
of the treatment period. Treatment was assessed as
being: very e¡ective, e¡ective, satisfactory, ine¡ective
or very ine¡ective.Demographic details andmedical his-
tory were recorded at the ¢rst clinic visit.Clinic PEFwas
measured at each visit, while FEV1and forced vital capa-
city (FVC)weremeasuredusing clinic spirometers at vis-
its1,1a, 2, 4, and 6. Patients did not use studymedication
or oral bronchodilators for 12h prior to each visit, and
did not use relief medication for up to 4h beforehand.
Details of changes in concomitant medications for asth-
ma, adverse events and other disorders were recorded
at each clinic visit.
Statistical analysis
All statistical tests were two-sided, with treatments
compared in a pairwise manner. Analyses were carried
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all patients randomised to treatment with completed
case report forms and veri¢able data. Analyses were
conducted on data at baseline (last 2 weeks of run-in),
months 1,2,3 and 6, and also for the whole treatment
period.
Primary e⁄cacymeasures were change from baseline
in mean absolute morning PEF (amPEF) over the 6-
month treatment period and the 24-week exacerbation
rate.Treatment groups were compared using theVan El-
teren test, adjusting for countryof recruitment, for both
amPEF and exacerbation rates, with patients included in
the analysis where they completed the treatment phase.
Additional supporting analyses were also carried out.
For amPEF, a repeatedmeasures analysis also controlling
for country of recruitment was conducted. For exacer-
bations, the number of patients with at least one severe
and one moderate or severe exacerbation during the
treatment phase was calculated and treatments com-
pared using the normal approximation to the binomial
distribution.
The study planned to recruit176 patients per group (a
total of 528 patients) in order to have at least 90% power
to detect (i) a mean treatment di¡erence of 5% at week
24 for change from baseline in amPEF (as % of post-
bronchodilator PEF), assuming a standard deviation of
11.5% and (ii) a mean treatment di¡erence of 0.9 exacer-
bations per 24 weeks with a standard deviation of1.2 ex-
acerbations per 24 weeks. In order to deal with
multiplicity, the threshold for establishing statistical sig-
ni¢cance was lowered from a=5^1.7% (i.e. from Pr0.05
to Pr0.017). Prior to analysis of the data, and before un-
blinding treatment allocation, it was decided to change
the primary outcome measure to change in mean abso-
lute amPEF (from change inmean amPEF as a percentage
of post-bronchodilator PEF). The planned sample size
was su⁄cient to enable detection of a clinically relevant
treatment di¡erence in this endpoint.
Secondary e⁄cacy measures included evening PEF
(pmPEF), asthma symptoms on wakening, day- and
night-time asthma symptoms, use of relief medication
(pu¡s of salbutamol), withdrawals due to lack of e⁄cacy
and patient/physician global assessment of treatment ef-
¢cacy. Secondary e⁄cacy variables (symptoms, use of
relief medication and physician/patients assessments)
were compared using the van Elteren method. For each
patient, the percentage of symptom-free days and
nights (i.e. with a score of 0) was calculated for
months 1,2,3 and 6, and changes from baseline (last 2
weeks of the run-in period) at each of these time points
were comparedbetween treatmentgroups. Percentages
of relief medication-free days and nights were cal-
culated and compared over thewhole treatment period.
Within patient/physician changes in e⁄cacy scores
(week 24 compared with week 0) were calculated and
compared.RESULTS
Of the 859 patients recruited into the study, 502 patients
were randomised to receive treatment allocation. Com-
pleted and veri¢able case report forms were collected
from 496 patients who were included in the intent-to-
treatpopulation.Threehundredand¢fty^ sevenpatients
were withdrawn prior to randomisation: 77% of these
patients no longer ful¢lled the study entry criteria be-
cause their asthma symptoms and/or PEF improved sub-
stantially during the run-in period on FP250mg b.d.
Patients were well matched between groups for age,
sex, lung function, smoking history, asthma duration
and severity, and the dose of pre-study ICS (Table1). Pa-
tients were symptomatic on ICS (BDP or BUD equiva-
lent) at a dosage of 500^800mg b.d. The number of
patients taking additional asthma medications was
evenly distributed between the treatment groups with
11 (2%) receiving anti-allergics, 30 (6%) receiving anticho-
linergics and 52 (10%) receiving xanthines.
Over the 6-month treatment period, amPEF, in-
creased from baseline values in all groups (Fig. 1). The
mean improvement was signi¢cantly greater with SM/
FP250 (42 l/min at endpoint) compared with either dose
of FP (16.5 and 16.9 l/min with FP500 and FP250, respec-
tively; Po0.001). By the end of the ¢rst week of treat-
ment there was a mean increase in amPEF of 35.6 L/min
with SM/FP250 which was more than 3 times the in-
crease seen with FP500 (9.6 l/min, Po0.001) and 4 times
that seenwithFP250 alone (7.5 l/min Po0.001).Therewas
no di¡erence in the improvementbetweeneitherdose of
FP alone.
SM/FP250 signi¢cantly reduced diurnal variation in
PEF. The mean change from baseline was 4.9% for the
SM/FP250 group compared with 3.0% for the FP500
and 2.2% for the FP250 groups (both Po0.001). Mean
pmPEF increased by 31.1l/min with SM/FP at the end of 6
months comparedwith 9.5 l/min for FP500 and15.4 l/min
for FP250.FEV1and FVC showed almostno change in any
treatment group between baseline and 6 months. How-
ever, mean clinic measured PEF increased from 387 to
420, 396 to 402 and 387 to 407 l/min with SM/FP250,
high-and low-dose FP, respectively, over the same
period.
Improvements in symptom-free days and nights fol-
lowed a similar pattern with the greatest, sustained im-
provements occurring in the combination group. The
proportion of symptom-free days and nights signi¢cantly
increased with SM/FP250 compared with either dose of
FP alone (Fig. 2). By the end of the study, the median
change from baseline in percentage of symptom-free
days was 21% with SM/FP250 compared to 1.5% with
FP500 and 0% with FP250 (both P=0.002). The median
change from baseline in % of symptom-free nights at
month six was 15%, 2% and 0%, respectively, (both
Pr0.002). SM/FP250 resulted in a signi¢cantly greater
TABLE 1. Demographic andbaseline characteristics (intention-to-treat population)
Patientcharacteristics SM/FP250 (n= 171) FP250 (n= 160) FP500 (n= 165)
No. (%)
Male 70 (41) 78 (49) 82 (50)
Female 101 (59) 82 (51) 83 (50)
Mean age (years7SD) 44.8715.6 45.7715.2 43.9714.9
Meanlung function (7SD)
amPEF (l/min) 347793 3477101 3577104
pmPEF (l/min) 377798 3727106 3857109
PEF (% of PEFbd) 78.979.7 77.678.7 79.478.8
PEFam (% predicted) 75.4717.4 73.6718.6 74.5719.0
PEF diurnalvariation (%) 11.176.3 10.275.8 10.376.5
FEV1 (l) 2.370.9 2.270.8 2.470.9
Median duration of asthma (years) 12.0 11.0 15.0
(range) 0.2^64.0 0.4^65.0 1.0^68.0
No. smokers (%)
Current 23 (13) 25 (16) 39 (24)
Previous 68 (40) 51 (32) 48 (29)
Never 80 (47) 84 (53) 78 (47)
Median ICS dailydose prior to study (mg)
BUD/BDP 1000 1000 1000
FP 500 500 750
No. of patients (%) with asthma deterioration
inpast year requiring:
Hospitalisations None 134 (78) 123 (77) 136 (82)
One 26 (15) 27 (17) 21 (13)
Z Two 11 (6) 10 (6) 8 (5)
Oral corticosteroids None 59 (35) 47 (29) 57 (35)
One 54 (32) 59 (37) 45 (27)
Z Two 57 (34) 54 (34) 62 (38)
Not speci¢ed 1 (o1) 0 1 (o1)
Other therapychanges None 27 (16) 16 (10) 24 (15)
One 34 (20) 49 (31) 42 (25)
Z Two 108 (64) 94 (59) 99 (60)
Not speci¢ed 2 (1) 1 (o1) 0
558 RESPIRATORYMEDICINEmedian % of days with no requirement for relief medica-
tion (53%) compared with FP500 (9%) and FP250 (15%)
(both Pr0.001). Similarly, the median percentage of
nights with no use of relief medication (salbutamol) was
signi¢cantly higher with SM/FP250 (90%) comparedwith
FP500 (77%) or FP250 (78%) (both Pr0.001).
Although patients were recruited on the basis of hav-
ing hadmore than two exacerbations over the past year,
the majority of those who completed the study had no
exacerbations during the 6-month treatment period
(66% of the SM/FP250 group, 59% of the FP250 group
and 65% of the FP500 group). The severe exacerbation
rates during the study (i.e. number of severe exacerba-
tions/patient/year) were low in all three groups with the
combination group reporting one-third that of the rate
with FP alone: 0.05 with SM/FP250, 0.16 with FP500 and
0.23 with FP250 (Fig. 3). The moderate exacerbation
rates were low in all groups, being 0.77 per patient per
year with SM/FP, and 0.95 for both high-and low-doseFP. Less than 6% of patients (27/496) experienced a se-
vere exacerbation during the study: 3% (5 patients) with
SM/FP250; 6% (10) with FP500 and 8% (12) with FP250
(Fig. 3). The di¡erence between combination treatment
and high or low-dose FP was not statistically signi¢cant
(P=0.16 and 0.059, respectively).Therewere also no di¡er-
ences between treatments in the number of patients ex-
periencing at least onemoderate or severe exacerbation
during the treatment period: 27% (47 patients) with SM/
FP250 compared with 31% (51) with FP500 and 35% (56)
with FP250.Mildexacerbationswerereportedby12%pa-
tients in each treatement group.
Treatment at the end of the study, as evaluated by the
physician, was considered an improvement over pre-
study treatment in 63% of patients receiving SM/FP250
compared with 44 and 47% with high-and low-dose FP
(both Pr0.006).
Only 64 (13%) of patients withdrew from the study
during the treatment period: SM/FP250 (27); FP500
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FIG 1. Changes from baseline in mean morning and evening
PEF during 6 months of study treatment.Results are expressed
as the mean7standard error. (&) salmeterol/FP (50/250 mg
b.d., n= 171); (*) FP (500mcg b.d., n= 165); (^) FP (250 mg
b.d., n= 160).
SALMETEROLADDEDTOFLUTICASONE INASTHMA 559(22); FP250 (15).Themost common reasons were failure
to return for clinic visits (¢ve patients in each group) and
adverse events: SM/FP250 (7); FP500 (6); FP250 (2).Only
12 patients withdrew due to lack of e⁄cacy.
DISCUSSION
Improvements in amPEF, and diurnal variation, symp-
toms and use of relief medication were signi¢cantly
greater with SM/FP250 compared with FP500 or FP250,
with no di¡erencebetween the two FP doses; these ¢nd-
ings were consistent throughout the 6 months, with no
evidence of tolerance and a low incidence of exacerba-
tions.These data con¢rm that the addition of salmeterol
to low-dose FP is more e¡ective than maintaining or
doubling the dose of FP in improving lung function and
asthma symptoms in patients who were previously un-
controlled onmoderate doses of ICS.
The study was completed in 100 asthma clinics both
within thehospital setting andingeneralpractices across
six di¡erent countries. Although there is the potential
for greater variability, the careful standardisation of pro-
cedures to ensure consistency in such a large number of
study centres validates the ¢ndings in a representativegroup of patients making the results widely applicable in
themanagement of asthma.
Study design
Previous studies of the e¡ects of adding a long-acting b-
agonist have been criticised for not including a control
arm receiving minimal or no intervention. The current
study addresses this criticism. Inclusion of a control
group (the FP250 arm) con¢rms that the e¡ects ob-
servedwere attributable to the addition of the long-act-
ing b-agonist, rather than being a trial e¡ect. In addition
the 4-week run-in period provided a baseline to over-
come the potentially confounding e¡ects of changing
the ICS and anypossible studybias. Itwas consideredun-
ethical to include a placebo group in such a population
withmoderate-to-severe, poorly controlled, asthma.
The design of our study contrasts with that of the FA-
CET study which also investigated exacerbations in a
moderate patient population (9). FACETwas a12-month
trial during which the e¡ects of two doses of the ICS bu-
desonide (BUD200 vs. 800mg) daily,with or without for-
moterol 12mg, were studied in 852 asthma patients.
However, patients in the FACET study received a much
higher dose of BUD during the run-in than in the treat-
ment phase: patients received 1600mg daily in the 4-
week run inperiodbeforerandomisation to a lowerdaily
dose of BUD alone, or BUD plus formoterol. In the pre-
sent study, patients either remained on the same dose of
FP alone (FP250), had salmeterol added to this dose of FP
(SM/FP250) or received double the dose of ICS alone
(FP500).
There are currently no standard de¢nitions for ‘ex-
acerbation’ for use in clinical trials.The FACETstudy, for
example, used a di¡erent de¢nition compared to this
study and this and other di¡erences in design may ac-
count for di¡erentoverall rates of exacerbations.Thede-
¢nition of exacerbations used in the present study has
been previously established (4).
Dose^response to £uticasone propionate
Marked improvements in lung function and symptoms
were apparent at the end of the run-in period on FP250
b.d.Three-quarters of thosewithdrawing from the study
after the run-in periodwere no longer symptomatic and
therefore were not eligible to enter the treatment
phase, even though they had previously been sympto-
matic on up to BDP 1000^1600 mcg daily prior to the
study. Patients randomised to receive this dose of FP
continued to improve over the 6-month treatment peri-
od. Continuation of this minimum intervention arm
(FP250) throughout the study period demonstrated that
doubling the dose of FP had no signi¢cant e¡ect on out-
comes, except a trend towards a decrease in exacerba-
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FIG. 2. Median change frombaseline in percentage of patientswho experienced no day- or night-time symptoms during treatment
with (&) salmeterol/FP (50/250 mgb.d.); (&) FP (500 mg b.d.); ( ) FP (250 mg b.d.).
560 RESPIRATORYMEDICINEtions.This indicates thatpatientswere at the top of their
steroid dose-response curve; this is an important result
because these asthmatic patients were relatively severe
and unstable and would have been candidates for in-
creased doses of ICS.No additional bene¢t in this study
was observed from doubling the FP dose, even over 6
months.However, it should be noted that, due to the ef-
¢cacyof low-dose FP, therewas a reduction in thepower
of the study to show a di¡erencebetween the two doses
of FP. Also, it would be of interest to include other end-
points such as bronchial responsiveness and in£amma-
tory markers in future studies. Our ¢nding, that there
was no di¡erencebetween the two doses of FP, is consis-
tent with a recent meta-analysis (14) which suggested
that the dose^response curve for £uticasone propio-
nate peaks at around 500mg daily. This £at dose^response curve contrastswith the ¢ndings of theFACET
study (9), where there were signi¢cant di¡erences be-
tween low- and high-dose budesonide.
Adding salmeterol
Signi¢cant and sustained additional bene¢t was gained
from adding salmeterol in the patients receiving FP250
who appeared to be at the top of their steroid dose^re-
sponse curve. Regular treatment with short-acting b2-
agonists has been suggested to cause long-term loss of
asthma control (15), and it has been questionedwhether
this e¡ectmay also be observedwith long-acting b-ago-
nists.The ¢ndings from previous long-term studies indi-
cated that there was no tachyphylaxis to the
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FIG. 3. Moderate and severe exacerbationrates during the12-monthspre-study (&) andduring study treatement (&) with salme-
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SALMETEROLADDEDTOFLUTICASONE INASTHMA 561bronchodilating e¡ects of salmeterol (16^18) although a
study in exercise-induced asthma did report a reduced
duration of bronchodilation after 1 month’s treatment
(19). Lack of tachyphylaxis is further con¢rmed in our
study by the daily morning and evening PEF results,
which showed no evidence of tolerance to the broncho-
dilating e¡ects of salmeterol. Symptom control was
maintained throughout the 6-month treatment period
andrates of exacerbations remained low in all groups, in-
dicating that patients were equally well-controlled with
SM/FP250 and the higher dose of FP.This is in contrast to
the FACET study (9), where formoterol/BUD reduced
therate ofmild and severe exacerbations comparedwith
double the dose of BUD.However, de¢nitions of exacer-
bationsweremore severe in our study and this, together
with the di¡erences in study design, may explain these
results. In our study, half or fewer of the patients receiv-
ing SM/FP250 experienced a severe exacerbation com-
pared to either dose of FP alone. However, signi¢cant
di¡erences were not detected between groups because
the overall number of exacerbations during the study
was less than expected despite the fact that all patients
were required to have hadmore than two exacerbationsduring the year prior to entry in the study.The possible
reason for the low exacerbation rates during treatment
compared with pre-study, may be due to the e¡ective-
ness of FP250, or may be related to poor compliance
with pre-studymedication as patients in both FP groups
showed similar compliance.
In summary, adding a long-acting b-agonist to the
treatment of patients who are symptomatic on low^
moderate dose inhaled steroids has already been shown
to produce signi¢cant bene¢ts comparedwith increasing
the dose of inhaled steroids (4^10) By including a control
arm our study clearly demonstrates, for the ¢rst time,
that these e¡ects are notrelated to changing the inhaled
corticosteroid or participation in a clinical trial, but are
due to the addition of salmeterol.
Acknowledgements
Funding for the study (SLGQ97 ^ J121) was provided by
GlaxoWellcome Research and Development.We thank
Stephen Pyke and Anne Cheesbrough for statistical ad-
vice and Sarah Gee and Ruth Murray for writing and
562 RESPIRATORYMEDICINEediting assistance during the preparation of this manu-
script.
The Study was previously presented at the European
Respiratory Society Annual Congress, Berlin,Germany,
September 20^24 and the American Thoracic Society
Annual Congress, Chicago, USA, April 24^29 1998 and
published as abstracts in Eur Respir J1997; 10:1S and Am J
Respir Crit Care Med1998; 157: A415 and A416
REFERENCES
1. The British Thoracic Society, The National Asthma Campaign, The
Royal College of Physicians of London et al, The British Guidelines
on Asthma Management 1995 Review and Position Statement.
Thorax 1997; 52: S1–S21.
2. International consensus report on the diagnosis and management
of asthma. Clin Allergy 1992; 22: 1–72.
3. Global Initiative for Asthma. National Institutes of Health, National
Heart, Lung and Blood Institute. Publication No. 95-3659,1995.
[Chapter 7] p. 70–117.
4. Greening AP, Ind PW, Northfield M, Shaw G. Added salmeterol
versus higher-dose corticosteroid in asthma patients with symptoms
on existing inhaled corticosteroid. Lancet 1994; 344: 219–224
5. Woolcock A, Lundback B, Ringdal N, Jacques LA. Comparison of
addition of salmeterol to inhaled steroids with doubling of the dose
of inhaled steroids. Am JRespir Crit Care Med 1996; 153: 1481–1488.
6. Faurschou P, Steffensen I, Jacques L. Effect of addition of inhaled
salmeterol to the treatment of moderate-to-severe asthmatics
uncontrolled on high-dose inhaled steroids. Eur Respir J 1996; 9:
1885–1890.
7. Condemi JJ, Goldstein S, Kalberg C, Yancey S, Emmett A, Rickard
K. The addition of salmeterol to FP versus increasing the dose of
FP in patients with persistent asthma. Salmeterol Study Group.
Ann Allergy Asthma Immunol 1999; 82: 383–389.
8. van Noord JA, Schreurs AJ, Mol SJ, Mulder PG. Addition of
salmeterol versus doubling the dose of FP in patients with mild to
moderate asthma. Thorax 1999; 54: 207–212.9. Pauwels RA, Lofdahl CG, Postma DS, et al. Effect of inhaled
formoterol and BUD on exacerbations of asthma. Formoterol and
Corticosteroids Establishing Therapy (FACET) International Study
Group. NEngl J Med 1997; 337: 1405–1411.
10. Shrewsbury S, Pyke S, Britton M. Meta-analysis of increased dose
of inhaled steroid or addition of salmeterol in symptomatic asthma
(MIASMA). BMJ 2000; 320: 1368–1373.
11. Lim S, Jatakanon A, Gordon D, et al. Comparison of high dose
inhaled steroids, low dose inhaled steroids plus low dose
theophylline, and low dose inhaled steroids alone in chronic
asthma in general practice. Thorax 2000; 55: 837–841.
12. Declaration of Helsinki. Recommendations guiding physicians in
biomedical research involving human subjects. 48th General
Assembly, Somerset West, Republic of South Africa, October
1996.
13. Quanjer PH, Tammeling GJ, Cotes JE, et al. Lung volumes and
forced ventilatory flows. Report of Working Party for Standardi-
zation of Lung Function Tests. European Community for Coal and
Steel. Official statement of the European Respiratory Society.
EurRespir J 1993; 16: Suppl 5–40S.
14. Holt S, Suder A, Weatherall M, et al. Dose–response relation of
inhaled fluticasone propionate in adolescents and adults with
asthma: meta-analysis. BMJ 2001; 323: 1–8.
15. Sears MR, Taylor DR, Print CG, etal. Regular inhaled beta-agonist
treatment in bronchial asthma. Lancet 1990; 336: 1391–1396.
16. Britton MG, Earnshaw JS, Palmer JB. A twelve month comparison
of salmeterol with salbutamol in asthmatic patients. European
Study Group. Eur Respir J 1992; 5: 1062–1067.
17. Lundback B, Rawlinson DW, Palmer JB. Twelve month comparison
of salmeterol and salbutamol as dry powder formulations
in asthmatic patients. European Study Group. Thorax 1993; 48:
148–153.
18. Taylor DR, Town GI, Herbison GP, et al. Asthma control during
long-term treatment with regular inhaled salbutamol and salme-
terol. Thorax 1998; 53: 744–752.
19. Nelson JA, Strauss L, Skowronski M, Ciufo R, Novak R, McFadden
ER. Effect of long-term salmeterol treatment on exercise-induced
asthma. NEngl J Med 1998; 339: 141F146.
